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Background: The National Malaria Control Programme in Senegal, introduced since 2006, artemisinin-based
combination therapy (ACT administration) for the treatment of uncomplicated malaria cases. In this framework, an
anti-malarial pharmacovigilance plan was developed and implemented in all public health services. This study
investigated the occurrence of Adverse Drug Events (ADEs) after ACT.
Methods: The study was conducted between January 2007 and December 2009. It was based on spontaneous
reports of ADEs in public health facilities. Data on patient demographic characteristics, dispensing facility, adverse
signs and symptoms and causality were collected from a total of 123 patients.
Results: The age range of these patients was six months to 93 years with a mean of 25.9 years. Of the reported
symptoms, 46.7% were related to the abdomen and the digestive system. Symptoms related to the nervous system,
skin and subcutaneous tissue, circulatory and respiratory systems and general symptoms and signs were 7%, 9.7%,
3.5% and 31.3%, respectively. Causality results linked 14.3% of symptoms to FalcimonW (Artesunate-Amodiaquine)
with certainty. Effects were classified as mild and severe in 69.1% and 7.3% of cases respectively while 23.6% were
serious. All patients with serious ADEs were hospitalized. One death was reported in a patient who had taken 24
pills at once.
Conclusion: These results confirm the need to develop and implement pharmacovigilance systems in malaria
endemic countries in order to monitor the safety of anti-malarial treatments.
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Early diagnosis and prompt treatment with an effective
anti-malarial drug remains a priority for the National
Malaria Control Programme (NMCP) in Senegal. This
strategy was threatened by the spread of chloroquine
resistance and the NMCP adopted artemisinin-based
combination therapy (ACT) in line with WHO treatment
guidelines. In Senegal, two combinations are recom-
mended as first-line treatment for uncomplicated malaria
cases: artesunate-amodiaquine (AS-AQ) and artemether-
lumefantrine (AL). In 2006, with the financial support of
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reproduction in any medium, provided the orthe AS-AQ combination was scaled up in the Senegalese
health care system [1].
ACT is based on a combination of drugs some of
which have been recently marketed. Safety profile data
for their long-term use in the general population in sub-
Saharan Africa are scarce. Several studies have reported
safe use of ACT, particularly the AS-AQ combination
[2], but there is little data outside of clinical trials. Post-
market safety data are important and must be collected
and analysed in a standard way, considering that patients
in endemic areas are likely to receive repeated anti-
malarial treatment in the course of a year [3]. Unfortu-
nately, in developing countries the incidence of adverse
events in the general population is under-recognized [4],
because the post-marketing drug surveillance systemstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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which explains why these countries have a low level of
case reporting [5]. In most of these countries, lack of
expertise and resources present barriers to a functional
pharmacovigilance system. This phenomenon was reported
in a recent study which stressed the lack of systematic and
consistent inclusion of pharmacovigilance activities and
requested funding support in proposals and in-country
plans [6]. In the same study, a lack of consistency across
proposals in what was defined and reported as pharmaco-
vigilance demonstrated the need for stronger efforts to
advance the role and effectiveness of pharmacovigilance
activities to support malaria control and prevention
programmes.
In Senegal, a national pharmacovigilance system based
at the National Centre of Pharmacovigilance (“Centre
Antipoison”) was created in 1998, but it was not scaled up
and therefore the reporting was very poor until recently.
Since 2009 Senegal has been a member of the WHO Col-
laborative Programme for International Drug Monitoring,
based at the Uppsala Monitoring Centre, Sweden. Because
pharmacovigilance should be an essential component for
all public health programmes that use medicines, there
was need to develop a pharmacovigilance system for anti-
malarials and in particular for ACT as part of the intro-
duction plan of these new drugs. This brought together
the competencies of the Ministry of health, the National
Centre of Pharmacovigilance, academic and private sectors
and partners such as WHO, UNICEF, USAID and civil
society organisations under the coordination of the NMCP
to develop and implement a dedicated safety monitoring
system of antimalarial drugs in all the public health
services in Senegal in 2007.
This paper reports Adverse Drug Events (ADEs) collected
in health facilities after anti-malarial treatment between
January 2007 and December 2009.
Methods
Study setting
Senegal is a West African country, with a population of
approximately 12,141,673 inhabitants (2010). Malaria is
endemic with a high transmission season between July
and November. The entire country’s population is at risk
of malaria.
Malaria case management is integrated into primary
health services. Health services are provided nationwide
through 75 health districts, which cover 78 district
hospitals and 1,018 health posts. Implementation of the
pharmacovigilance system involves all public health fa-
cilities. Between April 2006 and June 2009, artesunate +
amodiaquine (AS + AQ) in a co-blister was used to treat
uncomplicated malaria. In July 2009, co-blisters were
replaced by fixed dose artesunate-amodiaquine (AS-AQ
fixed dose). Drugs cost 0.6 US$ per course for adultsand 0.3 US$ per course for children during the period
covered by the study.
The treatment was administered once a day for three
days using the following drugs:
Between April 2006 and June 2009: AS + AQ in
co-blistered or FalcimonW (Cipla, India). It contains
50 mg of AS per tablet and 153 mg AQ base per tablet.
The recommended doses were 4 mg/kg/day for AS and
10 mg/kg/day for AQ. The product was available in
three formulations: three AS tablets and three AQ
tablets for children 0–6 years, six AS tablets and six AQ
tablets for children 6–13 years and 12 AS tablets and
12 AQ tablets for adults ≥ 14 years.
From July to December 2009: AS-AQ fixed-dose
co-formulation or ASAQ WinthropW (Sanofi-Aventis).
There were four different formulations: AS 25 mg and AQ
base 67,5 mg tablets for children 2–11 months; AS 50 mg
and AQ base 135 mg tablets for children 1–5 years; and
AS 100 mg and AQ base 270 mg tablets for children 6–13
years (three tablets) and for adults ≥ 14 years (six tablets).
This study was conducted countrywide and patients
have been reported by public health facilities located in
different regions in Senegal. All patients who received
partial or full treatment of ACT and who presented
ADEs which had been reported by health providers,
were enrolled in the study.Study design
This study is a retrospective analysis of ADEs cases
related to ACT as self-reported by patients at health
facilities during a period of three years.Data collection and analysis
Data were collected by health workers using the standard
ADEs reporting form developed by the Ministry of Health.
Collected data were:(i) the patient (age, sex, identification
number, antecedents, risk factor), (ii) all the drugs used by
the patients (names, dose, dosage form, route, start/stop
dates), (iii) the adverse reactions presented by the patient
(date of onset, symptoms and signs, evolution), (iv) and
the reporter (name, address, telephone, email).
When an ADE was diagnosed, the health worker filled
the standard form and sent it out to the NMCP focal point
for case management and pharmacovigilance through the
District Health Officer. All forms were checked and vali-
dated, including telephoning the reporter if necessary. In
all cases a letter was sent to the reporter to acknowledge
receipt of the form.
After validation the forms were sent to the National
Centre of Pharmacovigilance (Centre Antipoison) for caus-
ality analysis. Afterwards all reported cases and causality
results were recorded in the NMCP pharmacovigilance
database using MicrosoftW Excel programme.
Table 1 Distribution of cases according to age groups
Ages (years) N %






Over 55 5 4%
Not specified 3 2.4%
Total 123 100%
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Intensity of events was defined using the Moroccan
pharmacovigilance centre grades, which identifies three
grades of intensity: serious, severe and mild [7]. Serious:
a serious adverse event was defined as one that was fatal,
life-threatening, caused or prolonged hospital admission,
caused persistent incapacity or disability, or caused con-
genital anomaly. Severe: ADE not serious, but drugs must
be discontinued and an additional treatment initiated.
Mild: minor symptoms, neither serious nor severe
Causality
This is the relationship between the ADEs and the ACT.
Causality was determined using the WHO method. The
WHO causality categories benefit from long and exten-
sive use and have the advantage of being internationally
agreed and easy to use. The WHO method has six caus-
ality categories [8]. Causality assessment was performed
on a daily basis by a team which includes a medical
doctor, a pharmacist and a pharmacologist. Each quarter
the results are reviewed and endorsed by the pharma-
covigilance technical committee. An annual report is
prepared and presented by the technical committee to the
National Pharmacovigilance Advisory Committee, which
involves all stakeholders.
The WHO causality categories are: (1) Certain: clinical
event occurring in a plausible time relationship to drug
administration, which cannot be explained by concur-
rent disease or other drugs of chemicals. The response
to withdrawal of the drugs (dechallenge) should be
clinically plausible. Finally, the event must be definitive
pharmacologically or phenomenologically, using a satis-
factory rechallenge procedure if necessary. (2) Probably/
Likely: clinical event with a reasonable time sequence to
administration of the drug; unlikely to be attributed to
concurrent disease or other drugs or chemicals, which
follows a clinically reasonable response on withdrawal
(dechallenge). Rechallenge information is not required
to fulfil this definition. (3) Possible: clinical event, with a
reasonable time sequence to administrations of the drug,
but which could also be explained by concurrent disease
or other drugs or chemicals. Information on drug with-
drawal may be lacking or unclear. (4) Unlikely: Clinical
event with a temporal relationship to drug administra-
tion which makes a causal relationship improbable, and
in which other drugs, chemicals or underlying disease
provide plausible explanations. (5) Conditional/Unclassi-
fied: Clinical event, reported as an adverse reaction, about
which more data is essential for a proper assessment, or
the additional data is under examination. (6) Unassessa-
ble/Unclassifiable: a report suggesting an adverse reaction
which cannot be judged because information is insufficient
or contradictory, and which cannot be supplemented or
verified.Data analysis was done using Stata 11. Age was treated
as a categorical variable using strata. In addition age and
appearance of ADEs were summarized as means. Other
socio-demographic variables and safety indicators were
presented as frequencies and percentages. Incidence of
ADEs was calculated using the number of treatment
distributed per year. Lastly signs and symptoms have
been classified on the basis of the International
Statistical Classification of Diseases and Related Health
Problems, 10th Revision (ICD-10) [9].
Ethical considerations
This intervention was administered by the Ministry
of Health and included in the routine work of health
workers according to its malaria policy. Institutional
Review Board clearance was not required.
Results
Socio-demographic characteristics
Between 1st January 2007 and 31st December 2009, a
total of 123 patients with ADEs related to ACT were
reported. The mean age of patients was 25.9 years
(range 6 months-93 years) with a F/M sex ratio of 1.12
(Table 1). Sixty seven percent of the notifications were
gathered from public health posts while district hospi-
tals reported 30.1% of the ADEs. Only 2.4% of ADEs
were collected from private health facilities. Nurses
represented 86% of reporters while physicians and
midwives represented 13% and 1% respectively.
Reporting rate
There was on average 10 reported ADEs per 100 000
treatments distributed per year and an increase in the
incidence of reported events between 2007 and 2009
according to consumed treatments (Table 2).
Symptoms and signs
In total 227 signs and symptoms were collected among
123 patients. This represents on average two symptoms
per patient. Thirty six per cent of patients present only





Incidence of ADEs (per 100000
treatments)
2007 64 990341 6.5
2008 34 338335 10
2009 25 184170 13.6
Table 3 Classification of symptoms and signs
Systems Symptoms and signs Frequency
Digestive system and
abdomen N* = 106 46.7%




















system N = 8 3.5%
Hiccough 2
Dyspnoea 3
Low blood pressure 3
General symptoms and signs
N = 71 31.3%
Fever 4
Headache 7








Others N = 4 1.8% Visual disorders 2
Myalgia 1
Fixed stare 1
*N = number of reaction terms and the percentage is of a total of 227 terms.
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itus and urticaria. The adverse events had appeared within
a mean of 1.6 days (range 0 to 14 days) after the beginning
of therapy while the duration of ADEs varied from less
than 24 hours to 32 days. The events were reported follow-
ing the use of three different combination therapies:
AS +AQ co-blister, AS-AQ fixed dose and artesunate-
mefloquine (AS-MFQ). Eighty five percent of the notifica-
tions were related to the AS +AQ coblister, while 14% were
related to AS-AQ fixed dose and one reported case was
related to AS-MFQ.
Gastrointestinal disorders represented 46.7% of symp-
toms and signs reported, followed by general symptoms
and signs (31.3%). Disorders of the skin and cutaneous
system, nervous system and circulatory and respiratory
systems represented 9.7%, 7% and 3.5% of the effects
respectively (Table 3).
Seriousness
ADEs were classified as mild in 69.1% of cases and 7.3%
severe, while 23.6% of ADEs were serious. The percentage
of serious effects was about two times higher with the
AS-AQ co-blister than the fixed dose (25.7% vs. 11.7%).
All the serious ADEs were hospitalized and there was one
death due to misuse of drug. The patient was a 42-year
old man who had taken all the 24 tablets of AS-AQ at
once together with paracetamol and ciprofloxacin tablets.
On the same day he overdosed, he had presented with
movement disorders, vertigo, dyspnoea and hiccough and
was admitted in a rural district hospital before he died.
Causality
Using the WHO Causality criteria, 14.3% of ADEs related
to AS-AQ co-blister treatment were classified as Certain.
The main symptoms were nausea and vomiting, abdom-
inal pains, diarrhoea, extra pyramidal and movement
disorders, pruritus, urticaria, dyspnoea and hiccough.
22.8% and 37.2% of ADEs related to this combination were
classified as Probable and Possible respectively. Twenty-
seven reports were classified as Unlikely, Conditional/
Unclassified or Unassessable/Unclassifiable. None of the
events linked to use of the AS-AQ fixed dose were classi-
fied as Certain. However 23.5% of cases were classified as
Probable and 53% as Possible. The main effects reported
were nausea and vomiting, pruritus, vertigo, fatigue,
tinnitus and confusion. Four reports were classified asUnlikely or Unassessable/Unclassifiable. One ADE related
to AS-MFQ was reported. The patient presented with
pruritus which was classified as Probably linked to this
drug.
Discussion
With the wide use of ACT in endemic areas, safety moni-
toring of anti-malarial drugs is critical. This study serves
to reinforce previous reports advocating for increased
pharmacovigilance on adverse drug events of artemisinin-
based combination therapy, particularly in Africa [10-12].
While there exist several pre-clinical safety profile reports
on different forms of ACT, pharmacovigilance-based
reports on these combinations are scarce particularly in
sub-Saharan Africa, a major market for these drugs.
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eral health posts. Because routine spontaneous reporting
relies on vigilance of health workers, all the ADEs may
not be fully reported, this could lead to a low reporting
rate. Even though data were limited and based on pas-
sive reporting, the causality classifications support a link
between the adverse events and administration of ACT.
Adverse drug events are different from adverse drug
reactions. While an adverse event is any undesirable
medical occurrence that develops after administration of
a drug, regardless of the suspected relationship between
the drug product and the event, to classify the event as
an adverse drug reaction, a causal relationship must be
established [3].
One difficulty in this study was distinguishing between
adverse events and common symptoms of malaria [2].
Indeed symptoms presented by patients were not docu-
mented before treatment in the standard form to make
correct difference between malaria signs and ADEs
symptoms. But this was considered during the causality
analysis as the WHO method takes into account the fact
that the events could also be explained by concurrent
disease or other drugs or chemicals. It was also difficult
to establish whether patients were admitted in hospital
because of the seriousness of the symptoms or because
health workers wanted to avoid evolution to complicated
malaria by administering parenteral treatment to prevent
deterioration in the patient’s condition [13].
The apparent incidence of ADEs is far less than the
results of a clinical trial conducted in Senegal. That is
undoubtedly a reflection of the nature of the reporting
scheme, which relies on busy nurses and other health
professionals to report adverse events they suspect are
related to the anti-malarial medications. In addition, no
biological effects have been reported because all the
ADEs were collected from peripheral health facilities
where there is no laboratory service [14]. The frequency
of gastro-intestinal symptoms related to AS-AQ has
been reported by others studies [2,15]. All the serious
events were linked to artesunate-amodiaquine, particu-
larly with the co-blister combination, which has been
used for a longer period of time in comparison to other
combinations. All patients recovered. The only case of
death reported was due to a misuse of the drug.
This study’s findings confirm the relative safety of use
of ACT as reported by previous studies [2,14,15]. Most
of the ADEs were expected as they are mentioned in the
Summary of Products Characteristics (SPC). A few gen-
eral symptoms and signs and extra pyramidal reactions
were unexpected and, therefore, not found in the SPC.
Our series reported 6 cases of extrapyramidal reactions
among 4 children and 2 adults. A recent publication
supports an association of the use of AS-AQ combin-
ation therapy with acute extrapyramidal reactions, whichoccurred with recommended, and in some instances
reduced, daily doses [16].
Conclusion
Although endemic countries may have inadequate
infrastructure and limited resources for implementing
pharmacovigilance, drug safety monitoring mechanisms
are imperative. This study demonstrates the feasibility
and the need to set up a safety monitoring system for
anti-malarial drugs within a national pharmacovigilance
system. The latter should be scaled up in health facilities
and hospitals and involve all health workers to improve
the notification of adverse drug events of ACT. Even
though the safety of ACT is established, post-marketing
safety monitoring of ADEs is critical and should be
developed and implemented in endemic areas. Further-
more because many endemic countries are scaling up
malaria case management at community level, and given
that people living in malaria areas can receive more than
one course of treatment a year, the safety monitoring
system of ACT should not only involve health facilities
but also be extended at community level.
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